K Nakagawa

Summary

Affiliation: Kinki University
Country: Japan

Publications

  1. ncbi Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)
    Kazuhiko Nakagawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 7:1296-303. 2012
  2. ncbi A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours
    K Nakagawa
    Kinki University School of Medicine, Osakasayama, 589 8511, Japan
    Br J Cancer 95:677-82. 2006
  3. ncbi Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
    K Nakagawa
    Kinki University School of Medicine, Osaka, Japan
    Ann Oncol 14:922-30. 2003
  4. ncbi Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors
    Kazuhiko Nakagawa
    Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 0014, Japan
    Jpn J Clin Oncol 39:116-23. 2009
  5. ncbi Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients
    Kazuhiko Nakagawa
    Kinki University School of Medicine, Medical Oncology, 377 2 Ohnohigashi, Osakasayama 589 8511, Japan
    Jpn J Clin Oncol 38:339-46. 2008
  6. ncbi Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
    Y Akashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 98:749-55. 2008
  7. ncbi Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    K Takeda
    Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan
    Ann Oncol 20:835-41. 2009
  8. ncbi A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 103:6-11. 2010
  9. ncbi Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 106:763-7. 2012
  10. ncbi Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
    N Masuda
    Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Osaka, Japan
    Br J Cancer 68:777-82. 1993

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. ncbi Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)
    Kazuhiko Nakagawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 7:1296-303. 2012
    ..To investigate erlotinib safety and efficacy in Japanese patients, a large-scale surveillance study was implemented...
  2. ncbi A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours
    K Nakagawa
    Kinki University School of Medicine, Osakasayama, 589 8511, Japan
    Br J Cancer 95:677-82. 2006
    ..Pemetrexed with FA/VB(12) showed a tolerable toxicity profile and potent antitumour activity against NSCLC in this study...
  3. ncbi Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
    K Nakagawa
    Kinki University School of Medicine, Osaka, Japan
    Ann Oncol 14:922-30. 2003
    ..Thirty-one patients were included...
  4. ncbi Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors
    Kazuhiko Nakagawa
    Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 0014, Japan
    Jpn J Clin Oncol 39:116-23. 2009
    ....
  5. ncbi Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients
    Kazuhiko Nakagawa
    Kinki University School of Medicine, Medical Oncology, 377 2 Ohnohigashi, Osakasayama 589 8511, Japan
    Jpn J Clin Oncol 38:339-46. 2008
    ..This Phase I/II study was conducted to determine the recommended dose (RD) (Phase I) of Pem/Cis, and evaluate the efficacy and safety (Phase II) in Japanese MPM patients...
  6. ncbi Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
    Y Akashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 98:749-55. 2008
    ..Nimotuzumab enhanced the antitumor efficacy of radiation in certain human NSCLC cell lines in vitro and in vivo. This effect may be related to the level of EGFR expression on the cell surface rather than to EGFR mutation...
  7. ncbi Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    K Takeda
    Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan
    Ann Oncol 20:835-41. 2009
    ..This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated non-small-cell lung cancer (NSCLC)...
  8. ncbi A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 103:6-11. 2010
    ..This study aimed to evaluate the safety and efficacy of dose-dense weekly chemotherapy, followed by resection and/or thoracic radiotherapy...
  9. ncbi Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 106:763-7. 2012
    ....
  10. ncbi Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
    N Masuda
    Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Osaka, Japan
    Br J Cancer 68:777-82. 1993
    ..There were one complete response (7%) and five partial responses (36%) among the 14 patients for an overall response rate of 43%. The recommended dose for Phase II studies is 80 mg m-2 of CPT-11 and 60 mg m-2 of cisplatin...
  11. ncbi A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 99:852-7. 2008
    ..Preoperative DP was associated with encouraging resection rate and DFS data, and phase III trials for c-stage IB/II NSCLC are warranted...
  12. ncbi Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1647-56. 2010
    ..The addition of TS-targeting drugs to BIBW2992 is a promising strategy to overcome EGFR-TKI resistance in NSCLC with the T790M mutation of EGFR...
  13. ncbi Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification
    J Tanizaki
    Department of Medical Oncology, Kinki University, Ohno Higashi, Osaka Sayama, Japan
    Oncogene 30:4097-106. 2011
    ..Our results thus suggest that inhibition of both PI3K-survivin and MEK-ERK-BIM pathways is required for effective induction of apoptosis in breast cancer cells with HER2 amplification...
  14. ncbi Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial
    K Higuchi
    Department of Gastroenterology, Graduate School of Medicine, Osaka City University, 1 4 3 Asahimachi, Abeno Ku, Osaka, 545 8585, Japan
    Inflammopharmacology 14:226-30. 2006
    ..1%, 16/38) (P = 0.021). In conclusion, the present study demonstrated that lafutidine, as compared to famotidine, yields a significantly superior QOUH in patients with gastric ulcers in the clinical setting...
  15. ncbi Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
    T Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:36-42. 2010
    ..We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor of survivin expression, and platinum compounds (cisplatin and carboplatin) on human non-small cell lung cancer (NSCLC) cell lines...
  16. ncbi Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
    T Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 90:2092-6. 2004
    ..This combination chemotherapy warrants a phase II study and further evaluation in prospective randomised trials with cisplatin- or carboplatin-based combinations as first-line chemotherapy for advanced NSCLC...
  17. ncbi Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Japan
    Clin Cancer Res 15:907-13. 2009
    ..We have now investigated whether addition of the oral fluoropyrimidine derivative S-1 to gefitinib might overcome gefitinib resistance in NSCLC cell lines...
  18. ncbi Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer
    Nobuyuki Yamamoto
    Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 58:285-91. 2006
    ....
  19. ncbi Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
    N Yamamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 8511, Japan
    Br J Cancer 90:87-92. 2004
    ..01); diarrhoea was more common with DI (P=0.01). Three treatment-related deaths occurred in DC patients. In conclusion, although the DI and DC regimens had different toxicity profiles, there was no significant difference in survival...
  20. ncbi A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 101:1549-54. 2009
    ..To evaluate the safety and efficacy of dose-dense weekly chemotherapy in the treatment of advanced thymoma...
  21. ncbi Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 104:1594-601. 2011
    ..We have now investigated the effect of TS overexpression on pemetrexed sensitivity in NSCLC cells...
  22. ncbi Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...
  23. ncbi Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines
    Tsutomu Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Clin Cancer Res 14:6496-504. 2008
    ..We have now investigated the effect of YM155, a small-molecule inhibitor of survivin expression, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to gamma-radiation...
  24. ncbi Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification
    Junko Tanizaki
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1198-207. 2010
    ..Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification...
  25. ncbi Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
    Shinzoh Kudoh
    Department of Respiratory Medicine, Osaka City University Medical School, Osaka, Japan
    J Clin Oncol 24:3657-63. 2006
    ..This randomized phase III trial evaluated the efficacy and safety of docetaxel versus vinorelbine (the current standard treatment) in elderly patients...
  26. ncbi Identification of thymidylate synthase as a potential therapeutic target for lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:354-61. 2010
    ..Although inhibition of TS has an antiproliferative effect in cancer cells, the precise mechanism of this effect has remained unclear...
  27. ncbi Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:807-13. 2011
    ..MET is a receptor tyrosine kinase (RTK) whose gene is amplified in various tumour types. We investigated the roles and mechanisms of RTK heterodimerisation in lung cancer with MET amplification...
  28. ncbi A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer
    Kaoru Matsui
    Medical Center for Respiratory and Allergic Diseases of Osaka Prefecture, Osaka, Japan
    Jpn J Clin Oncol 35:181-7. 2005
    ..This study was conducted to determine and evaluate the recommended regimen of gemcitabine-docetaxel and evaluated its efficacy and safety in chemonaive Japanese NSCLC patients...
  29. ncbi Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301
    Masashi Kobayashi
    Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
    J Thorac Oncol 5:1075-80. 2010
    ..Amrubicin, a novel 9-aminoanthracycline, inhibits topoisomerase II. We investigated a sequential triplet chemotherapy consisting of irinotecan and cisplatin followed by amrubicin in patients with extensive-stage SCLC...
  30. ncbi Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer
    H Kaneda
    Department of Genome Biology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:1210-7. 2011
    ..We found that inhibin β A subunit (INHBA) mRNA is overexpressed in gastric cancer (GC) specimens and investigated the effect of activin A, a homodimer of INHBA, on angiogenesis in GC...
  31. ncbi [In these days molecule target drug in advanced non-small cell lung cancer]
    M Miyazaki
    Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Japan
    Kyobu Geka 60:1177-83. 2007
    ..Until the present that stracture have been participate T790M for acquired resistance and amplification of the MET gene is another mechanism of acquired resistance to EGFR-TKI...
  32. ncbi The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
    Y Akashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 96:1532-9. 2007
    ..Combined treatment with TZT-1027 and radiation therefore warrants investigation in clinical trials as a potential anticancer strategy...
  33. ncbi Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
    ....
  34. ncbi A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial
    Takayasu Kurata
    Department of Medical Oncology, Kinki University, School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 4:644-8. 2009
    ..A phase I study on relapsed small cell lung cancer (SCLC) was conducted to establish the toxicity and maximum tolerated dose of carboplatin with topotecan, and to observe the antitumor activity...
  35. ncbi Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 3:1073-5. 2008
    ..Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure...
  36. ncbi Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401)
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 5:105-9. 2010
    ..We have performed a multicenter phase II trial to evaluate the efficacy and safety of amrubicin for patients with previously treated non-small cell lung cancer (NSCLC)...
  37. ncbi Hyperventilation and cold-pressor stress echocardiography for noninvasive diagnosis of coronary artery spasm
    Y Hirano
    First Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan
    J Am Soc Echocardiogr 14:626-33. 2001
    ..Hyperventilation and cold-pressor stress echocardiography is thus a noninvasive and useful tool for the diagnosis of vasospastic angina...
  38. ncbi Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:222-6. 2010
    ..However, little is known about changes in the GH-IGF-1 axis in cancer patients...
  39. ncbi Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
    Toshio Shimizu
    Department of Medical Oncology, Kinki University Nara Hospital, 1248 1 Otoda cho, Ikoma, Nara, 630 0293, Japan
    Int J Clin Oncol 12:218-23. 2007
    ..The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005...
  40. ncbi Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
    ....
  41. ncbi Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:17-23. 2010
    ..To determine the pharmacokinetics and safety of RAD001 (everolimus) in Japanese patients with advanced solid tumors...
  42. ncbi Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010
    ....
  43. ncbi Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors
    Taroh Satoh
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 15:3872-80. 2009
    ..The aim of this study was to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetics, and antitumor activity of YM155 in patients with advanced refractory solid tumors...
  44. ncbi Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:2825-33. 2010
    ..In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active...
  45. ncbi Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 28:844-53. 2010
    ..This phase I trial was conducted to evaluate drug safety and pharmacokinetics as well as tumor response of sorafenib in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)...
  46. ncbi Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 70:168-73. 2010
    ..The primary objectives of this study were to determine the recommended dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell lung cancer (NSCLC)...
  47. ncbi Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 14:5250-4. 2008
    ..To evaluate the efficacy and toxicity of combination therapy with the oral fluoropyrimidine formulation S-1 and irinotecan for patients with advanced NSCLC...
  48. ncbi De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer
    Masayuki Takeda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 5:399-400. 2010
    ..We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC...
  49. ncbi Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients
    Kunio Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:54-9. 2010
    ..The optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established...
  50. ncbi Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002)
    Yasumasa Nishimura
    Department of Radiation Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Radiat Oncol Biol Phys 69:786-92. 2007
    ....
  51. ncbi Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 1:684-91. 2006
    ....
  52. ncbi Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
    Lung Cancer 46:247-54. 2004
    ..CONCLUSIONS: Gefitinib provided clinical benefit for the following factors 'female', 'good PS' and 'non-smoker'. A low smoking index is reported as a novel predictive prognostic factor following a single regimen of gefitinib...
  53. ncbi A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:992-4. 2010
    ..We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies...
  54. ncbi Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
    Masahiro Fukuoka
    Fourth Department of Internal Medicine, Kinki University School of Medicine, 377 2 Ohnohigashi Osakasayama, Osaka 589, Japan
    J Clin Oncol 21:2237-46. 2003
    ....
  55. ncbi Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
    W Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:407-12. 2011
    ....
  56. ncbi Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
    ..These results reveal distinct biochemical properties of endogenous mutant forms of EGFR expressed in NSCLC cell lines and may have implications for treatment of this condition...
  57. ncbi Pemetrexed-induced edema of the eyelid
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 54:241-2. 2006
    ..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known...
  58. ncbi A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka 589-8511, Japan
    Anticancer Res 26:2479-85. 2006
    ..CONCLUSION: These data suggest that the combination of CPT-11 and AMR is not tolerated, as it mediates an unexpectedly strong myelosuppressive effect, and is inactive against both NSCLC and SCLC...
  59. ncbi Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells
    Tsutomu Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Clin Cancer Res 15:5117-25. 2009
    ..We have now investigated the effect of CP-751,871, a fully human monoclonal antibody specific for IGF-IR, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to radiation...
  60. ncbi The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    FEBS Lett 582:4125-30. 2008
    ..Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin...
  61. ncbi Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan
    Junji Tsurutani
    Fourth Department of Internal Medicine, Kinki University School of Medicine, Ohonohigashi 377 2, Osakasayama, Osaka 589 8511, Japan
    Lung Cancer 35:299-304. 2002
    ..However, the significance of top1 mutations to CPT resistance needs to be further investigated...
  62. ncbi Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Sci 101:167-72. 2010
    ..These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification...
  63. ncbi Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Int J Cancer 122:1530-8. 2008
    ....
  64. ncbi Risk factors that discriminate 'high- risk' from 'low-risk' Japanese patients with coronary artery disease
    K Miwa
    The Second Department of Internal Medicine, Kansai Electric Power Hospital, Osaka, Japan
    Jpn Circ J 64:825-30. 2000
    ..Among patients with a significant coronary stenosis or left ventricular dysfunction, a low serum level of HDL-cholesterol was the only significant predictor for high-risk CAD...
  65. ncbi Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    H Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Japan
    Ann Oncol 23:1537-41. 2012
    ..We examined the relation between postprogression survival (PPS) and OS in phase III trials of first-line chemotherapy for advanced NSCLC...
  66. ncbi Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer
    Nobuyuki Yamamoto
    Kinki University School of Medicine, Department of Medical Oncology, Japan
    Anticancer Res 26:777-81. 2006
    ..Paclitaxel, administered as a weekly infusion at a dose of 80 mg/m2, was effective in treating relapsed and refractory SCLC...
  67. ncbi Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells
    Takefumi Komiya
    Division of Medical Oncology, Kinki University School of Medicine, 377 2 Ohnohigashi, 589 8511, Osakasayama City, Osaka, Japan
    Cancer Chemother Pharmacol 51:202-8. 2003
    ..The objective of this study was to determine the cytotoxicity of ritterazine B to non-small-cell lung cancer (NSCLC) cells in vitro and its effects on the cell cycle and apoptosis...
  68. ncbi Mutational analysis of the beta-tubulin gene in lung cancer
    Junji Tsurutani
    Fourth Department of Internal Medicine, Kinki University School of Medicine, Ohonohigashi 377-2, Osakasayama, 589-8511, Osaka, Japan
    Lung Cancer 35:11-6. 2002
    ..Further investigations are needed to clarify the mechanism of drug resistance...
  69. ncbi Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation
    Ryotaro Morinaga
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 58:411-3. 2007
    ..This case suggests that the activating EGFR mutations may confer the pathogenesis of a subset of SCLC...
  70. ncbi Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer
    Ryotaro Morinaga
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Sci 99:2455-60. 2008
    ..009) but not with FISH positivity (P = 0.266). Our results therefore suggest the existence of a significant association between EGFR mutation and EGFR amplification in patients with advanced NSCLC...
  71. ncbi Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Sakai Hospital, Osaka, Japan
    Cancer Res 69:6515-21. 2009
    ..Our results thus suggest that sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type KRAS and C-RAF in those with mutant KRAS...
  72. ncbi Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease
    Y Fujiwara
    Department of Gastroenterology, Osaka City University Graduate School of Medicine, Asahimachi, Osaka, Japan
    Aliment Pharmacol Ther 21:10-8. 2005
    ..The efficacy of acid-suppressive drugs for non-erosive gastro-oesophageal reflux disease in Japan, in which the prevalence of Helicobacter pylori infection is higher compared with Western countries, is unknown...
  73. ncbi Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells
    Masato Ikeda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Lett 248:292-8. 2007
    ..Furthermore, depletion of survivin resulted in G(2)-M arrest, suggesting that down-regulation of survivin by p53 contributes to the p53-dependent G(2)-M checkpoint triggered by DNA damage...
  74. ncbi Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin
    Kimio Yonesaka
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 118:812-20. 2006
    ..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53...
  75. ncbi Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition
    Wataru Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1188-97. 2010
    ..Our results suggest that c-Src is a promising target for the treatment of gastric cancer and that analysis of MET amplification might optimize patient selection for treatment with c-Src inhibitors...
  76. ncbi FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth
    Hiroyasu Kaneda
    Department of Genome Biology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Res 70:2053-63. 2010
    ..In conclusion, FOXQ1 is overexpressed in CRC and enhances tumorigenicity and tumor growth presumably through its angiogenic and antiapoptotic effects. Our findings show that FOXQ1 is a new member of the cancer-related FOX family...
  77. ncbi Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 3:187-9. 2008
    ..Furthermore, the tumor was confirmed immunohistochemically to produce AFP. To our knowledge, this is the first report of a LCNEC that produces AFP...
  78. ncbi SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion
    Kaoru Tanaka
    Department of Genome Biology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 124:1072-80. 2009
    ..In conclusion, the overexpression of SRPX2 enhances cellular migration and adhesion in gastric cancer cells. Here, we report that the biological functions of SRPX2 include cellular migration and adhesion to cancer cells...
  79. ncbi [ZD1839]
    Kazuhiko Nakagawa
    Fourth Department of Internal Medicine, Kinki University School of Medicine
    Nippon Rinsho 60:378-83. 2002
  80. ncbi Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer
    Hiroshi Saito
    Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Japan
    Am J Clin Oncol 29:503-7. 2006
    ..The purpose of this study is to evaluate the efficacy, safety and dose-intensity as a measure of the feasibility of 3-week scheduling of irinotecan and cisplatin in patients with advanced NSCLC in phase II study...
  81. ncbi [A case of distant metastasis from advanced gastric cancer treated with TS-1, which maintained NC (no change) for 9 months]
    Koji Nakao
    Dept. of Surgery, Nishinomiya Kaisei Hospital
    Gan To Kagaku Ryoho 30:1505-9. 2003
    ..The patient had a performance status of 1 or 2, and kept a fair QOL. TS-1 is an excellent new anticancer agent and, we have high expectations for its use in combined therapy with other drugs...
  82. ncbi Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
    Soji Kakiuchi
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
    Hum Mol Genet 13:3029-43. 2004
    ..Our scoring system might eventually lead to achievement of personalized therapy for NSCLC patients...
  83. ncbi [Gefitinib in non-small cell lung cancer]
    Kazuhiko Nakagawa
    Department of Medical Oncology, Kinki University, School of Medicine
    Nippon Rinsho 62:1312-20. 2004
  84. ncbi Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report
    Yoshinori Fujiwara
    Second Department of Surgery, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, Hyogo 663, Japan
    Oncol Rep 14:1177-82. 2005
    ..Preoperative CRT should be given to patients with squamous cell carcinoma, while esophagectomy remains the standard therapy for responders and has a tolerable mortality...
  85. ncbi [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]
    Yutaka Nishiwaki
    National Cancer Center Hospital East
    Gan To Kagaku Ryoho 31:567-73. 2004
    ..Further studies are needed to identify factors affecting survival...
  86. ncbi Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer
    Gyo Asai
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    J Thorac Oncol 1:226-30. 2006
    ..This combination therapy must be planned only after careful consideration of the drug-drug interaction...
  87. ncbi Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902
    Hiroshi Saito
    Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki Aichi, Japan
    J Clin Oncol 24:5247-52. 2006
    ..We amended the protocol to evaluate IP after EP with concurrent twice-daily TRT in a single-arm phase II study because of an unacceptable toxicity in IPE...
  88. ncbi Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines
    Narikazu Boku
    Division of Gastrointestinal Oncology and Gastroenterology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 37:440-5. 2007
    ..This study aimed to clarify the efficacy and safety of L-OHP monotherapy in patients with metastatic colorectal cancer refractory to fluoropyrimidines...
  89. ncbi Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    Riichiroh Maruyama
    National Kyushu Cancer Center, Fukuoka, Japan
    J Clin Oncol 26:4244-52. 2008
    ..This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) with advanced/metastatic non-small-cell lung cancer (NSCLC) who had failed one or two chemotherapy regimens...
  90. ncbi Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104
    Nobuyuki Yamamoto
    Department of Thoracic Oncology, Shizuoka Cancer Center Hospital, Naga Izumi, Japan
    Cancer 107:599-605. 2006
    ..The authors conducted a randomized Phase II study of GC versus GV to compare them in terms of efficacy and toxicity...
  91. ncbi EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib
    Naruo Yoshimura
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, 1 4 3 Asahi machi, Osaka 545 8585, Japan
    Lung Cancer 51:363-8. 2006
    ..A brain MRI on March 4 showed that multiple brain metastases also had decreased in size. Based on RECIST criteria, they had stable disease but radiographic tumor regression was observed...
  92. ncbi A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer
    Katsuyuki Kiura
    Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 3:386-93. 2008
    ..Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan...
  93. ncbi A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer
    Ichinosuke Hyodo
    Division of Gastroenterology, University of Tsukuba, Tsukuba, Ibaraki 305 8575, Japan
    Jpn J Clin Oncol 36:410-7. 2006
    ..Therefore, we performed a phase II study to investigate the 3-week regimen of capecitabine in Japanese patients with metastatic colorectal cancer (MCRC)...
  94. ncbi [International clinical trials for a medical oncologist in Japan]
    Kazuhiko Nakagawa
    Department of Medical Oncology, Kinki University School of Medicine
    Gan To Kagaku Ryoho 34:320-3. 2007
    ....
  95. ncbi Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study
    Shoji Kudoh
    Nippon Medical School, Tokyo, Japan
    Am J Respir Crit Care Med 177:1348-57. 2008
    ..Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib...
  96. ncbi Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Clin Cancer Res 14:4206-12. 2008
    ..The objective of this study was to evaluate the efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B(12) in pretreated Japanese patients with advanced non-small cell lung cancer (NSCLC)...
  97. ncbi Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells
    Michihide Shimono
    Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Int J Oncol 30:835-40. 2007
    ..The findings suggest that the patient CD4 T-cells recognized the XAGE-1b 33-49-related epitope on autologous OU-LU-6 tumor cells in a manner restricted by DR *0901...
  98. ncbi Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors
    Shuichiro Sato
    Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Shikata cho, Okayama, Japan
    Cancer Immun 7:5. 2007
    ..These findings suggested that XAGE-1b is a promising target molecule for a cancer vaccine against lung cancer...
  99. ncbi Afferent loop obstruction with pancreatitis after distal partial gastrectomy with B-II reconstruction added Braun anastomosis for cancer of the stomach
    Koji Nakao
    Second Department of Surgery, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, Hyogo, 663, Japan
    Hepatogastroenterology 50:893-6. 2003
    ..Her clinical course subsequently improved and she was discharged on the 104th postoperative day. This paper describes the details of this unusual condition, and we discuss a review of the literature...
  100. ncbi Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate
    Takeyoshi Itsukuma
    Division of Hematology Oncology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
    J Gastroenterol 42:402-5. 2007
    ..Eighteen months later, however, the polyps were enlarged. In this patient, imatinib administration led to the remission of CML and might also have been responsible for the temporary regression of adenomatous polyps of FAP...
  101. ncbi Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma
    Ali Mohamed Ali Eldib
    Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Int J Cancer 108:558-63. 2004
    ..Those 8 sera were from patients with adenocarcinoma. These findings indicated strong immunogenicity of XAGE-1b in lung adenocarcinoma and suggested its potential use as a target for vaccine-based immunotherapies...